DDOG Craters 21% Post-Earnings as Options Traders Sought Cover
Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish
Datadog reported its Q3 numbers on November 4 and the market's verdict was swift: the stock fell 21.5% on the week to $220.52, a move that dwarfs the already-weak peer group, where FTNT dropped 30.8%, PANW fell 12.8%, and CRWD lost 8.7%.
Options traders had positioned for exactly this kind of volatility. The put/call ratio climbed to 0.95 by November 3, more than 2.6 standard deviations above its 20-day mean of 0.86, and near its 52-week high of 1.01. That is the heaviest demand for downside protection seen all year on this stock. The sharp spike in the PCR arrived as the stock was already sliding through the $270s and $260s in the days before the print, suggesting market participants were hedging into the announcement rather than reacting to it. The setup was notably different from a month ago, when the same ratio was sitting quietly below 0.86 and the lending market was similarly unstressed.
The borrow market tells a consistent story of low conviction on the short side, despite the stock's sharp drop. Availability remains essentially unlimited, with more than 330 million shares available to borrow against roughly 9.8 million currently shorted. Cost to borrow is just 0.34%, a rate that has barely moved over the past month. Short interest itself eased 1.1% on the week to 3.0% of the free float, continuing a gentle unwind from the 10.5 million shares shorted in early October. This is not a short-seller story. The decline was driven by long sellers, not a build in bearish positioning.
The Street entered the print with an unusually bullish tilt, and the initial post-earnings analyst reaction has been mixed at the margins. BTIG maintained its Buy but trimmed its target from $289 to $260, acknowledging the guide disappointed. Needham held firm at $300. Coming into the week, the target raises had been piling up: Wells Fargo to $325, UBS to $320, Oppenheimer to $330, Bernstein with an upgrade to Outperform at $350. The consensus mean is now sitting well above the current price. The bull case rests on 36% Q2 revenue growth, 80% gross margins, and broadening AI observability demand. The bear case centres on guided deceleration: management pointed to 28% to 29% growth in Q3 and roughly 25% in Q4, a step-down that the market appears to have discounted aggressively. The EV/EBITDA multiple is running near 55x, compressing on the week but still demanding relative to the revised growth trajectory.
Insider activity adds a secondary note. CTO Alexis Le-Quoc sold roughly 40,000 shares on October 28 at prices in the $276 to $284 range, generating around $11.9 million in proceeds. All transactions were conducted under a pre-arranged 10b5-1 plan, so the sales reflect a scheduled programme rather than a discretionary call on the stock. The 90-day net across insiders is negative $44.3 million, though again predominantly plan-driven.
The one historical earnings data point available here is from August 6, when Datadog fell 17.4% the day after its Q2 print and was still down 10.9% five days later. This week's move is in the same direction and of a similar magnitude, suggesting the market is applying a consistent framework: when guidance disappoints relative to a high-multiple setup, the stock re-rates sharply and the recovery is not immediate. With the earnings event now cleared, attention turns to whether the deceleration implied in the Q3 guide proves conservative or accurate when November data begins to accumulate.
Stocks in this article
See the live data behind this article on ORTEX.
Open DDOG on ORTEX →How this article was generated
- Generated
- 4 Nov 2026, 21:01
- Data as of
- 4 Nov 2026, 20:55
- Prompt version
- v1.0
- Data sources
- Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notesAlt DataPrevious Mi Articles
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.